Nanopore-based long-read sequencing technology offering a revolutionary change in the clinical routine of HLA genotyping.
HoloGRAFT™ is a the first laboratory kit monitoring absolute quantity of donor derived cfDNA.
Multiplex Assay and Software product for HLA typing that offers a single working-day workflow.
HLA typing Assay by NGS for use on Illumina® sequencers combined with HLA Twin Software.
What we do
Omixon is a molecular diagnostics company dedicated to transitioning the HLA community to Next Generation Sequencing (NGS) technologies.
Highest level of leadership
Our key opinion leaders and major collaborators in the HLA community have provided the highest level of leadership for several decades and helped pave the way for the adoption of NGS.
Omixon has evolved into a global molecular diagnostics company that is currently focused on driving the adoption of NGS in the clinic with Holotype HLA™ and other NGS-based HLA genotyping Assay and Software products.
NGS FOR HLA EXPERTS
Our flagship product Holotype HLA™ was designed in a clinical lab at the Children’s Hospital of Philadelphia by Professor Dimitri Monos. It is a combination NGS Assay and Software product for use on Illumina® sequencers.
Believe the data:
- 150+ HLA labs trained onsite worldwide
- 50+ HLA labs in clinical routine worldwide
- 20+ customers using CE-IVD products in Europe
- 12 labs ASHI or CAP accredited in North-America
- 20 labs EFI accredited in Europe